Track topics on Twitter Track topics that are important to you
-- Shipping Resumes for MicroCutter 5/80™ Stapler and Reloads --
Dextera Surgical Inc. (Nasdaq: DXTR), a company developing and commercializing the MicroCutter 5/80™ Stapler, today announced financial results for its fiscal fourth quarter and full year ended June 30, 2017. Management will hold a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide an update on the company’s business.
“We have identified and addressed the cause for the premature lock out of the MicroCutter 5/80 surgical stapler announced on July 6th, and after extensive in-house testing of the modification, we resumed shipping to our customers,” said Julian Nikolchev, president and CEO of Dextera Surgical Inc. “Simultaneously, after appropriate testing, we have implemented production changes for the reloads, allowing us to resume shipping, with expectations of fulfilling all backorders before the end of the quarter. We are excited to have the MicroCutter 5/80 back in the hands of surgeons to help enable less invasive surgical procedures.”
Recent Highlights and Accomplishments:
Fiscal 2017 Fourth Quarter Financial Results
Total product sales were approximately $1.0 million for the fiscal 2017 fourth quarter compared with $0.7 million for the same quarter of fiscal 2016. MicroCutter sales were approximately $359,000 in the fiscal 2017 fourth quarter with $75,000 in backorders compared to $516,000 of sales in the third quarter of fiscal 2017. The sequential decrease in MicroCutter product sales is due to a backorder for the blue reload cartridges for a portion of the fourth quarter and a shipping hold at the end of the fourth quarter of fiscal 2017. Total revenue was approximately $1.1 million for the fiscal 2017 fourth quarter compared with approximately $0.7 million for the fiscal 2016 fourth quarter.
Total operating costs and expenses for the fiscal 2017 fourth quarter were $4.0 million, compared with $4.8 million for the same period of fiscal 2016. Cost of product sales was approximately $1.0 million for the fourth quarter of fiscal 2017 compared with $1.1 million for the same period of 2016. Research and development expenses were $1.4 million for the fiscal 2017 fourth quarter, compared with $1.5 million for the fiscal 2016 fourth quarter. Selling, general and administrative expenses were $1.5 million for the fiscal 2017 fourth quarter compared with $2.2 million for the comparable period of fiscal 2016. Total Operating cost and expenses in the fourth quarter included a reversal of accrued incentive compensation expense of approximately $0.5 million.
The net loss for the fiscal 2017 fourth quarter before the deemed preferred stock dividend was approximately $3.1 million. Additionally, net loss applicable to common stockholders included a deemed (non-cash) preferred stock dividend of $4.0 million, representing the value of beneficial conversion rights embedded in the preferred shares issued in the company’s recently completed convertible preferred stock public offering. This amount was determined as the difference between fair value of common stock into which preferred shares are convertible and the proceeds of the financing allocated to the preferred shares. The total net loss attributable to common stockholders for the fiscal 2017 fourth quarter was $7.0 million, or $0.40 per share. Net loss attributable to common stockholders for the fiscal 2016 fourth quarter was approximately $4.2 million, or $0.47 per share.
Cash, cash equivalents and investments, as of June 30, 2017, were approximately $6.0 million, compared with approximately $2.5 million at March 31, 2017. This includes $6.7 million in net proceeds raised through a public equity offering in May 2017. As of June 30, 2017, there were approximately 40.3 million shares of common stock outstanding, which includes the conversion of all previously outstanding Series A convertible preferred stock and all but 273 shares of the Series B convertible preferred stock.
Management’s key objectives in the near term are as follows:
Conference Call Details
To access the live conference call on August 8, 2017, at 4:30 p.m. Eastern Time via phone, please dial 844-419-1785 from the United States and Canada or 216-562-0472. The conference ID is 61373128. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately four hours after the call through August 15, 2017, and may be accessed by dialing 855-859-2056 from the United States and Canada or 404-537-3406 internationally. The replay passcode is 61373128.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at ir.dexterasurgical.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.
The webcast is also being distributed through the Thomson StreetEvents Network. Institutional investors can access the call via Thomson StreetEvents at www.streetevents.com, a password-protected event management site.
About Dextera Surgical
Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.
Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.
The statements in this press release regarding Dextera Surgical’s expectations that it will fulfill all backorders before the end of August, and its management objectives under the caption “Milestones,” are "forward-looking statements." There are a number of important factors that could cause Dextera Surgical’s results to differ materially from those indicated by these forward-looking statements, including the risks detailed from time to time in Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, under the caption “Risk Factors.” Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
|Dextera Surgical Inc.|
|Consolidated Statements of Operations|
|(amounts in thousands except per share amounts)|
|Three months ended||Twelve months ended|
|June 30,||June 30,|
|Product sales, net||$||952||$||651||$||3,051||$||2,529|
|License and development revenue||82||48||302||1,460|
|Operating costs and expenses|
|Cost of product sales||1,034||1,074||3,798||3,897|
|Research and development||1,386||1,514||6,565||6,327|
|Selling, general and administrative||1,547||2,246||7,657||9,388|
|Total operating costs and expenses||3,967||4,834||18,020||19,612|
|Loss from operations||(2,917||)||(4,120||)||(14,597||)||(15,557||)|
|Interest and other income||3||18||15||67|
|Net loss before income tax benefit||(3,056||)||(4,231||)||(15,131||)||(15,987||)|
|Income tax benefit||-||-||-||-|
|Preferred stock deemed dividend||(3,980||)||-||(3,980||)||-|
|Net loss attributable to common stockholders||$||(7,036||)||$||(4,231||)||$||(19,111||)||$||(15,987||)|
|Basic and diluted net loss per share attributable to common stockholders||$||(0.40||)||$||(0.47||)||$||(1.71||)||$||(1.79||)|
|Shares used in computing basic and diluted net loss per share attributable to common stockholders||17,794||8,928||11,144||8,910|
|Consolidated Balance Sheets|
|(amounts in thousands)|
|June 30,||June 30,|
|Cash, cash equivalents and investments||$||6,010||$||12,716|
|Liabilities and stockholders' equity|
|Accounts payable and other liabilities||$||2,294||$||2,218|
|Long term debt||3,473||3,124|
|Total stockholders' equity||202||7,282|
|Total liabilities and stockholders' equity (deficit)||$||8,871||$||15,692|
Bob Newell, 650-331-7133
Vice President, Finance and Chief Financial Officer
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...